Allogene Therapeutics (ALLO) Depreciation and Depletion (2019 - 2024)

Allogene Therapeutics (ALLO) has 6 years of Depreciation and Depletion data on file, last reported at $3.6 million in Q1 2024.

• For the quarter ending Q1 2024, Depreciation and Depletion rose 1.37% year-over-year to $3.6 million; the trailing twelve-month figure through Mar 2024 stood at $14.2 million (up 0.97% YoY), and the FY2023 full-year result was $14.2 million, down 0.67% from the prior year.
• Depreciation and Depletion grew to $3.6 million in Q1 2024, from $3.5 million in the prior quarter.
• In the past five years, Depreciation and Depletion ranged from a high of $4.2 million in Q4 2021 to a low of $1.8 million in Q3 2020.
• A 5-year average of $2.9 million and a median of $3.5 million in 2023 frame the typical range for Depreciation and Depletion.
• Across the five-year window, Depreciation and Depletion surged 247.98% in 2020 and dropped 27.68% in 2022, its largest moves.
• Tracing ALLO's Depreciation and Depletion over 5 years: stood at $1.8 million in 2020, then surged by 130.04% to $4.2 million in 2021, then dropped by 27.68% to $3.1 million in 2022, then grew by 13.33% to $3.5 million in 2023, then increased by 2.24% to $3.6 million in 2024.
• Business Quant data shows ALLO's Depreciation and Depletion at $3.6 million in Q1 2024, $3.5 million in Q4 2023, and $3.6 million in Q3 2023.